tbuckley/cabot-search huggingface dataset:
Recombinant Human Granulocyte Colony-Stimulating Factor Hastens Granulocyte Recovery After High-Dose Chemotherapy and Autologous Bone Marrow Transplantation in Hodgkin's Disease
Authors: Kerry McD. Taylor, Sundar Jagannath, Gary Spitzer, Jorge A. Spinolo, Susan L. Tucker, Beverly Fogel, Fernando F. Cabanillas, Fredrick B. Hagemeister, Lawrence M. Souza
Journal: Journal of Clinical Oncology (1990)

The running head of the report by Taylor et al published in the December 1989 issue (J Clin Oncol 7:1791–1799, 1989) was incorrect. It should have read: "G-CSF AND ABMT IN HODGKIN'S DISEASE."
Severe Craniocerebral Trauma and Respiratory Abnormalities: I. Physiological Studies with Specific Reference to Effect of Tracheostomy on Survival
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In vivo monitoring with a fiber optic catheter
Authors: J. B. Taylor
Journal: JAMA (1972)

Fiber optic techniques lend themselves to continuous physiologic monitoring of an array of hemodynamic and other key variables in the critically ill. The factor limiting clinical application has been the rapid clot formation at the sensing tip. By developing a side-viewing fiber optic probe, clotting was prevented during prolonged periods of intravascular monitoring. The catheter has been adapted to monitor multiple physiologic changes, including cardiac output, oxygen saturation, dye clearance, intravascular pressure, and heart rhythm. The procedure has been well tolerated and has required but a minimum of bedside instrumentation. These preliminary studies were conducted in patients with acute myocardial infarction.
Animal drug teratogenicity: its application to man
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nitrite Inhalants: History, Epidemiology, and Possible Links to AIDS
Authors: Harry W. Haverkos, Andrea N. Kopstein, Hank Wilson, Peter Drotman
Journal: Environmental Health Perspectives (1994)

Nitrite inhalants have been commonly abused substances in the United States. Nitrite inhalants and AIDS was a popular topic in the early 1980s, when the cause of AIDS was not known. With the discovery of HIV, concern about nitrite use in the USA waned. However, nitrite inhalant use is associated with behavioral relapse and HIV transmission among gay men, with decreased lymphocyte counts and natural killer cell activity in a few laboratory studies, and it remains a candidate cofactor in the pathogenesis of AIDS-related Kaposi's sarcoma. Discouraging nitrite use continues to be a worthwhile public health goal.
Health in a developing world
Authors: M. Tavassoli
Journal: JAMA (1974)

Man in underdeveloped countries, or the disinherited in all parts of the world, perceives life not as a flowering or a development of an essential productiveness but as a permanent struggle against an omnipresent death.<sup>1</sup> Frantz Fanon THIS grim perception is reflected in several recent studies<sup>2,3</sup>that have disclosed two astounding trends. <h3>Two Trends</h3><h3>Trend of Health Indices.—</h3> During the first half of this century, modest progress was made towards improving world health. In the third quarter, progress halted or, worse, regressed. Virtually every measure of health care has remained static. Even more disturbing, the rates of improvement are worse in poor countries than in the rich. There is room for improvement that has not come about. For instance, the death rate from tuberculosis has remained static both in Chile and in the United States. But in Chile it is still five times higher than in the United
Childhood sclerodermatomyositis: report of a case with the anti-PM/Scl antibody and mechanic's hands
Authors: V. GARCIA-PATOS, R. BARTRALOT, V. FONOLLOSA, C. ARNAL, M. BORONAT, C. GELPI, J.L. RODR, A. CASTELLS
Journal: British Journal of Dermatology (1996)
THE EMOTIONS AS FACTORS IN THE ETIOLOGY OF DISEASE.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels
Authors: C Puoti, A Magrini, T Stati, P Rigato, F Montagnese, P Rossi, L Aldegheri, S Resta
Journal: Hepatology (1997)

This study was aimed to evaluate demographic, clinical, histological, and virological characteristics of 46 hepatitis C virus (HCV) carriers with persistently normal alanine transaminase (ALT) levels and to compare the results with those obtained in a group of 52 HCV-RNA-positive patients with elevated ALT levels. Subjects with normal ALT were more often females ( P &lt; .001), were more likely to be asymptomatic ( P &lt; .001), and have a lower incidence of risk factors for HCV transmission ( P &lt; .01). All patients with normal ALT had significant histological liver damage. The mean grading and staging did not differ between patients with normal and those with raised ALT concentrations. Moderate to severe hepatitis was more frequently found among subjects with normal than with elevated ALT. HCV genotype 2a was far more common in subjects with normal (43%) than with abnormal ALT levels (6%; P &lt; .002), genotype 1b being more frequent in these latter (50% vs. 17%; P &lt; .001). Patients with normal ALT levels had similar serum HCV-RNA titers than subjects with raised ALT. Neither HCV genotype distribution nor viral load correlated with the severity of liver damage. We conclude that significant liver disease may occur irrespective of clinical symptoms, ALT levels, HCV genotypes, and viral load.
Radiological Physicists
Authors: Walter G. Gunn
Journal: JAMA (1986)

If the worship of science and technology has become a secular form of religion in the 20th century, then surely many of its high priests must include the physicists who made seminal discoveries in the first half of the century. At hand is a slim volume touching the high points of the lives of ten of those physicists. Text, photographs, and sketches range from ten to 24 pages in individual chapters devoted to Roentgen, Curie, Planck, Rutherford, Bragg, Duane, Bohr, Joliot, Compton, and Fermi. These chapters provide significant biographical details, particularly including selected short quotes from writings and conversations. There are, in addition, short biographical notes on many other scientists, physicians, and engineers involved in the lives and activities of the central figures. There are also 403 separate references, a mine for the student or reader desiring to dig deeper. An inquiry into the private lives of these scientists permits
Methacholine challenge
Authors: I. J. Folk
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A7.17 Effects of baricitinib on multibiomarker disease activity scores and their components in a phase 2b study in moderate-to-severe rheumatoid arthritis patients
Authors: PC Taylor, MC Genovese, E Keystone, M Weinblatt, J Rancourt, E Nantz, DE Schlichting, SH Zuckerman, WL Macias
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Baricitinib, an oral inhibitor of JAK1 and JAK2 signalling, improved signs and symptoms in patients with active rheumatoid arthritis (RA) who were methotrexate inadequate responders (MTX-IR) in a double-blind, placebo (PBO) controlled study. We investigated how a quantitative, multibiomarker disease activity score (MBDA) and its components are affected by treatment with baricitinib 4mg (n = 50) once daily compared to PBO (n = 79) during 12 weeks' treatment in moderate-to-severe RA patients. <h3>Materials and methods</h3> Serum samples were collected at baseline and Weeks 4 and 12. MBDA scores and changes in individual MBDA components were subjected to post-hoc statistical analyses. <h3>Results</h3> At baseline, the proportion of patients with low, moderate, and high MBDA scores were similar in the 2 groups, as were median MBDA scores (PBO=44 vs. baricitinib=47). Unlike PBO-treated patients, baricitinib patients had decreased MBDA scores at 4 and 12 weeks compared to baseline (baricitinib=35.5 and 37.0 (p &lt; 0.001) vs. PBO=46.0 and 45.0, respectively). Baricitinib-treated patients had significant (p &lt; 0.05) median % decreases in MBDA components vs. PBO including C-Reactive Protein (-66.9 vs. 6.6/-56.1 vs. 8.2 at 4/12 weeks), Matrix metalloproteinase (MMP)-3 (-12.3 vs. 4.5/-14.5 vs. 6.3 at 4/12 weeks), serum amyloid A (-56.4 vs. 9.9/-37.6 vs. 9.2 at 4/12 weeks), soluble TNF receptor (-12.1 vs. -0.1/-12.0 vs. 1.2 at 4/12 weeks), VCAM-1 (-15.9 vs. 1.4/-12.1 vs. 1.0 at 4/12 weeks), and human cartilage glycoprotein 39; -26.2 vs. -0.5/-9.9 vs. -1.6 at 4/12 weeks). Compared to PBO, there were no significant changes for baricitinib-treated patients at either timepoint for epidermal growth factor (EGF), MMP-1, or vascular endothelial growth factor-A. For baricitinib-treated patients versus PBO, at 4 but not 12 weeks, Interleukin-6 and resistin were significantly decreased and at 12 but not 4 weeks, leptin was significantly increased. <h3>Conclusions</h3> Consistent with other indices of disease activity, the treatment of MTX-IR patients with baricitinib 4mg once daily resulted in a reduction in MBDA scores, by 4 weeks. Decreases in MBDA scores and the components were present at both 4 and 12 weeks. Reduction in the levels of inflammatory markers beyond those associated with an acute phase response is apparent in these patients.
Massachusetts Medical Society
Authors: Robert N. Nye, G. Colket Caner, Robert L. DeNormandie, John P. Monks, Francis P. Denny, A. W. Allen, E. D. Gardner, W. R. Morrison, Horatio Rogers, Edward J. O'Brien, E. S. Bagnall, Frank R. Ober, Leroy E. Parkins, W. Irving Clark, Louis R. Daniels, Henry R. Viets, Robert B. Osgood, Benjamin Spector, Guy L. Richardson
Journal: New England Journal of Medicine (1941)
Long periods in space flight may take physiological, psychological toll among crew
Authors: J. Smith
Journal: JAMA (1990)

GOING INTO SPACE in search of answers to medical and other questions is, of course, not without risk. In the movie "2001: A Space Odyssey," dogged by the deranged computer "HAL," astronauts had little time to worry about derangements in body physiology. In reality, however, long-term space travel sequelae such as bone demineralization and muscle atrophy merit the intense study being given to them by the National Aeronautics and Space Administration (NASA). Four major challenges impose limits on the duration of human space journeys: physiological deconditioning, ionizing radiation, psychological difficulties, and life support. Deconditioning is a serious concern, says a senior NASA astronaut, William Thornton, MD, adding: "If you go into space for 6 months without exercise, you may expect to be carried off when you get back." Thornton points up a basic fact: "The heart is nothing more than muscle. It will atrophy without the demands made on it
ORIGIN OF PIGMENT IN SKIN, AND THE NATURE OF CERTAIN PIGMENTED TUMORS ARISING IN THE SKIN.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AUTHORS' REPLY
Authors: J B Cookson, A G I Cookson
Journal: Thorax (1993)

<h3>Background</h3> Glutamate-cysteine ligase modifier (GCLM) subunits, combined with catalytic (GCLC) subunits, has been known for the first rate-limiting enzyme for glutathione (GSH) synthesis. Increasing studies have shown that the non-metabolic functions of many metabolic enzymes also play a crucial role in tumor progress. However, the non-metabolic functions of GCLM remain unexplored. Hence, we wonder if there are unorthodox functions of GCLM under redox stress participating colorectal Carcinoma(CRC) tumorigenesis. <h3>Methods</h3> Western blot, real-time quantitative PCR and immunohistochemical analysis were used to detect the relative expression of GCLM in cell lines and patients‘ specimens. The MTS assay, migration and invasion assay, sphere formation assay were performed to detect the functions of GCLM <i>in vitro</i>, and the xenograft models and PDX models in nude mice <i>in vivo</i>. Cytosolic and nuclear extraction, immunofluorescent analysis were used to show the location of GCLM. Chromatin immunoprecipitation (ChIP) assay was used to screen and verify the GCLM target genes. <h3>Results</h3> We found that glucose deprivation condition upregulated the expression of GCLM rather than hypoxia or H2O2. Compared to adjacent tumor tissues, the expression of GCLM was upregulated in CRC tumor tissues. The high expression of GCLM predicted poor prognosis in CRC patients. Inhibition of GCLM results in decreased proliferation rate, migration and invasion ability and sphere formation in HCT116 and DLD1 <i>in vitro</i>. Similarly, GCLM inhibition suppressed CRC tumorigenesis and metastasis in xenograft models and PDX models<i> in vivo</i>. The cancer cell stem cell markers were also downregulated after GCLM inhibition. Interestingly, we found that glucose starvation could rescue the anti-cancer phenotypes of GCLM inhibition and led to nucleus-translocation and accumulation of GCLM. ChIP assay showed GCLM could interact with octamer-binding transcription factor 4 (<i>OCT4)</i> promoter<i>,</i> a cancer stem cell marker, to increase its expression, and the target gene of <i>OCT4</i> showed a positive correlation with GCLM expression in CRC patients. <h3>Conclusions</h3> Our data showed that GCLM displayed nucleus accumulation in the condition of glucose deprivation which increased the transcription of <i>OCT4.</i> This study revealed an unorthodox oncogenic function of GCLM in colorectal carcinoma and suggested GCLM as a potential therapeutic target in CRC.
Coexistence of urinary calculi and vesicoureteral reflux
Authors: A. D. Amar
Journal: JAMA (1968)

Coexistence of vesicoureteral reflux and urinary calculi was noted in 16 patients. This new observation suggests that a patient with urinary calculi and urinary tract infection of long duration should be examined for reflux. After the removal of the stone (or stones) and appropriate anti-microbial therapy, if infection persists and reflux is believed to be an important etiologic factor, surgical correction of reflux may be considered.
PTH-049 Gastro-oesophageal mechanisms of recurrent postprandial vomiting in young patients with joint hypermobility syndrome and autonomic dysfunction
Authors: J Jafari, E Yazaki, R Shimono, Q Aziz, D Sifrim
Journal: Gut (2010)

<h3>Introduction</h3> We have recently demonstrated a high prevalence of functional GI disorders in patients with joint hypermobility syndrome.1 These patients frequently have autonomic nerves dysfunction and may present with recurrent vomiting, severe dyspepsia and constipation. We aimed to characterise the OGJ mechanisms underlying recurrent postprandial vomiting in a series of consecutive patients with joint hypermobility syndrome and/or autonomic dysfunction. <h3>Methods</h3> Twelve patients (mean age=25.5 years, 9 females, 3 males) referred for gastro-oesophageal motility testing due to recurrent postprandial vomiting were studied during fasting and postprandial periods using combined high-resolution manometry-impedance. Eating disorders, neurologic and other organic gastrointestinal disorders were previously excluded. Median duration of postprandial vomiting was 17 months. Using Beighton Hypermobility Score, 7/12 patients were diagnosed with Joint Hypermobility Syndrome (JHS). In five of these patients we found autonomic dysfunction symptoms. Combined stationary HRM-impedance (Sandhill Scientific) was performed in semirecumbent position. The protocol included 10 single wet swallows, 2 multiple rapid swallows sequences, a semisolid standard meal followed by 30 min postprandial monitoring. Chicago Classification 2009 was used to classify oesophageal motility disorders. <h3>Results</h3> Hiatus hernia was diagnosed in 4/12 patients. Normal oesophageal motility was observed in 6/12 patients and the remaining patients had intermittent hypotensive peristalsis. All patients vomited after the standard meal. Nausea preceding vomiting was present in only 5/12 patients. Aerophagia, objectively detected by impedance, was a major feature, found in 8/12 patients. However, only 4 patients had an impedance pattern of belching-liquid regurgitation. The majority of patients had objective abdominal straining (detected with HRM as abrupt, low amplitude, simultaneous increase in gastro-oesophageal pressure) followed by liquid intra-oesophageal retrograde flow with high proximal extent. <h3>Conclusion</h3> JHS was present in a significant proportion of these young patients with recurrent postprandial vomiting. Aerophagia was a significant consistent finding in these patients. We hypothesise that patients with JHS and oesophago-gastro-intestinal involvement may perceive early postprandial mild gastric discomfort (probably due to liquid accumulation in the gastric cardiac region) and develop an aerophagic behaviour to alleviate their discomfort by belching. Subsequently, straining to belch is associated with vomiting.
The Thoracic Surgical Patient—Preoperative, Anesthetic and Postoperative Care
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal